DNTH Dianthus Therapeutics, Inc. /DE/: institutional ownership and insider trading
287 funds reported holding $6.58B of Dianthus Therapeutics, Inc. /DE/ in their latest 13F filings; in Q2 2026 funds net bought $344M, with 58 new positions and 33 funds selling out; over the last 12 months insiders bought $0 and sold $71.2M on the open market.
DNTH revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$50.2M, EPS -0.90
- Quarter ended Mar 31, 2026: revenue n/a, net income −$40.8M, EPS -0.85
- Quarter ended Dec 31, 2025: revenue $284K, net income −$64.4M, EPS -1.53
- Quarter ended Sep 30, 2025: revenue $396K, net income −$36.8M, EPS -0.97
Famous investors holding DNTH
- Ken Griffin (Citadel Advisors): $100M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $10.5M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $8.95M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $4.18M, 0.0% of the portfolio
Largest institutional holders of DNTH
- FMR LLC — $799M
- BlackRock, Inc. (BLK) — $402M
- T. Rowe Price Investment Management, Inc. — $379M
- WELLINGTON MANAGEMENT GROUP LLP — $315M
- Fairmount Funds Management LLC — $247M
- PRICE T ROWE ASSOCIATES INC /MD/ — $245M
- STATE STREET CORP (STT, STT-PG) — $230M
- VANGUARD CAPITAL MANAGEMENT LLC — $211M
- Avidity Partners Management LP — $205M
- Octagon Capital Advisors LP — $180M
Recent DNTH insider trades
- Sep 17, 2026: Carr Edward sold 20,000 shares ($2.03M)
- Sep 1, 2026: Randhawa Simrat sold 23,124 shares ($2.46M)
- Aug 19, 2026: Read Simon sold 2,778 shares ($327K)
- Aug 10, 2026: Read Simon sold 2,777 shares ($304K)
5%+ owners
- T. Rowe Price Investment Management, Inc.: 12.1% (Schedule 13G/A, filed Aug 7, 2026)
- BlackRock, Inc.: 6.4% (Schedule 13G/A, filed Jul 28, 2026)
- Wellington Management Group LLP: 5.9% (Schedule 13G, filed Aug 13, 2026)
Who owns the most DNTH stock?
The largest institutional holders of Dianthus Therapeutics, Inc. /DE/ in the latest 13F filings are FMR LLC ($799M), BlackRock, Inc. (BLK) ($402M), T. Rowe Price Investment Management, Inc. ($379M).
Are insiders buying or selling DNTH?
Over the last 12 months insiders bought $0 and sold $71.2M of Dianthus Therapeutics, Inc. /DE/ stock on the open market (SEC Form 4).
Which famous investors own DNTH?
Ken Griffin, Two Sigma, Izzy Englander, D. E. Shaw.
Which ETFs hold DNTH?
90 ETFs and mutual funds hold it among their top 100 positions, including VGHAX, FDGRX, XBI, OTCFX.